Study S002316

A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic Solution for Injection 1.34mg/ml (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

ClinicalTrials.gov record

Registration

Registration: NCT05689372
Study type: OBSERVATIONAL
Status: ENROLLING_BY_INVITATION
Enrollment: 600
Start: 2026-02-02
Primary completion: 2026-11-30
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:1111-1243-9580

Registered primary outcomes

Number (incidence) of adverse events (AEs) [From baseline (week 0) to 26 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.